CLL (Chronic Lymphocytic Leukemia) Complete Guide: PBS Findings, Clinical Features, Diagnosis, and Prognosis

Chronic Lymphocytic Leukemia (CLL) is the most common leukemia in adults and is characterized by the abnormal proliferation of mature B lymphocytes. These cells gradually accumulate in the bone marrow, peripheral blood, and lymphoid tissues, leading to progressive immune dysfunction.

---

1️⃣ Key Characteristics of CLL

• Predominantly affects older adults (≥60 years)
• More common in males
• Slowly progressive; many patients are asymptomatic at diagnosis
• Marked lymphocytosis due to clonal B-cell expansion
• Progressive bone marrow infiltration
• Immune dysfunction → higher risk of infection

Some patients remain stable for years, while others develop symptoms requiring active treatment.

---

2️⃣ Peripheral Blood Smear (PBS) Findings

PBS plays an important role in raising suspicion for CLL.

Characteristic Findings

• Increased mature lymphocytes
  • Small, round cells with condensed chromatin
• Smudge cells (basket cells)
  • Fragile lymphocytes broken during slide preparation
  • A hallmark but not pathognomonic
• Occasional “turtle shell appearance”
  • Deeply clumped nuclear chromatin

Blood Count Changes

• Hemoglobin, platelets initially normal
• Cytopenias may appear as disease progresses (anemia, thrombocytopenia)

PBS alone is not diagnostic, but it guides further immunophenotyping.

---

3️⃣ Clinical Presentation

Asymptomatic Stage

• Most patients diagnosed incidentally during routine CBC testing

Symptomatic Disease

• Lymphadenopathy (cervical, axillary, inguinal)
• Hepatosplenomegaly
• Constitutional symptoms
  • Fatigue
  • Weight loss
  • Fever
  • Night sweats
• Recurrent infections (due to hypogammaglobulinemia)
• Bleeding tendencies (if thrombocytopenia develops)

---

4️⃣ Diagnosis

CLL is diagnosed primarily through hematologic and immunophenotypic evaluation.

1. CBC & PBS

• Persistent lymphocytosis
• Smudge cells
• Mature small lymphocytes

2. Immunophenotyping (Flow cytometry) – Essential for Diagnosis

Typical CLL B-cell markers:

• CD5+
• CD19+
• CD23+
• Light-chain restriction (κ or λ)

3. Bone Marrow Examination

• Not always required for diagnosis
• Useful for staging and cytopenia evaluation

4. Molecular & Cytogenetic Testing

Important for risk stratification:

• 17p deletion
• TP53 mutation
• IGHV mutation status
• Complex karyotype

In most cases, lymphocytosis + typical immunophenotype is sufficient for diagnosis.

---

5️⃣ Prognosis

CLL shows a wide spectrum of progression patterns—from indolent to aggressive.

Favorable Prognosis

• Mutated IGHV
• Absence of TP53/17p abnormalities

Poor Prognostic Indicators

• 17p deletion
• TP53 mutation
• Rapid lymphocyte doubling time
• Elevated β2-microglobulin

Treatment Approach

• Early-stage asymptomatic patients:
  → Watch & Wait (observation only)
• Indications for therapy:
  • Symptomatic lymphadenopathy or splenomegaly
  • Progressive cytopenias
  • B symptoms
  • Rapidly increasing lymphocyte count

Treatment Options

• BTK inhibitors (ibrutinib, acalabrutinib)
• BCL-2 inhibitor (venetoclax)
• Anti-CD20 antibodies (rituximab, obinutuzumab)
• Combination regimens

CLL is chronic but highly manageable with modern targeted therapies.

---

6️⃣ Summary

• CLL is a chronic B-cell lymphoproliferative disease.
• PBS: mature lymphocytosis, smudge cells, turtle shell appearance.
• Many patients asymptomatic; symptoms develop gradually.
• Diagnosis relies on flow cytometry showing CD5+, CD19+, CD23+ B cells.
• Prognosis depends strongly on genetic abnormalities.
• Treatment is initiated only when clinically necessary.

---

References

Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol. 2020.
Swerdlow SH, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC, 2017.
Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet. 2008.
Hallek M, Cheson BD. Clinical Practice Guidelines in CLL. Blood. 2018.
Bain BJ. Blood Cells: A Practical Guide. 5th ed. Wiley-Blackwell, 2015.